Kura Oncology, Inc. $KURA is Prosight Management LP’s 4th Largest Position

Prosight Management LP decreased its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 13.3% during the third quarter, Holdings Channel reports. The institutional investor owned 2,758,516 shares of the company’s stock after selling 422,668 shares during the quarter. Kura Oncology makes up approximately 5.7% of Prosight Management LP’s investment portfolio, making the stock its 4th largest position. Prosight Management LP’s holdings in Kura Oncology were worth $24,413,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Assenagon Asset Management S.A. boosted its position in Kura Oncology by 37.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,265,030 shares of the company’s stock worth $11,196,000 after purchasing an additional 345,951 shares in the last quarter. Sector Gamma AS acquired a new stake in shares of Kura Oncology during the 3rd quarter worth approximately $3,880,000. Nan Fung Trinity HK Ltd. purchased a new position in shares of Kura Oncology during the 3rd quarter valued at approximately $2,043,000. Los Angeles Capital Management LLC acquired a new position in shares of Kura Oncology in the 2nd quarter valued at $450,000. Finally, CWM LLC boosted its holdings in Kura Oncology by 185.9% during the third quarter. CWM LLC now owns 118,363 shares of the company’s stock worth $1,048,000 after buying an additional 76,957 shares in the last quarter.

Kura Oncology Price Performance

Kura Oncology stock opened at $8.65 on Friday. The stock has a market capitalization of $764.05 million, a P/E ratio of -2.72 and a beta of 0.22. The company’s fifty day moving average price is $8.62 and its 200 day moving average price is $9.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.06. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $12.49.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). The company had revenue of $17.34 million for the quarter, compared to analyst estimates of $34.71 million. Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%. As a group, equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Wedbush dropped their target price on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. UBS Group restated a “buy” rating and set a $15.00 target price (down from $16.00) on shares of Kura Oncology in a research report on Friday. Finally, Leerink Partners set a $20.00 price target on Kura Oncology and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $27.57.

Insider Activity

In related news, insider Francis Burrows sold 23,726 shares of Kura Oncology stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $9.78, for a total value of $232,040.28. Following the sale, the insider directly owned 33,735 shares in the company, valued at approximately $329,928.30. The trade was a 41.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 7,142 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $60,421.32. Following the sale, the senior vice president owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. This trade represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 59,794 shares of company stock worth $537,176. Company insiders own 6.40% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.